EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieRandomisierte kontrollierte Studie

Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus–Driven Oropharynx Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial

Haitham Mirghani iD, Anne Aupérin iD, Caroline Even, Alicia Larive, Jerome Fayette iD, Lionnel Geoffrois, Florian Clatot iD, Benoit Calderon, Yungan Tao, France Nguyen iD, Emmanuelle Fabiano iD, Sarah Kreps und 13 weitere

Journal of Clinical Oncology · 2026

DOI: 10.1200/jco-25-00835 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2026. Verfasst von Haitham Mirghani und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oto-rhino-laryngology and Head and Neck Surgery, Hôpital Européen Georges Pompidou, AP-HP, University Paris Cité, Paris, France. Hauptthemen laut MEDLINE: Oropharyngeal Neoplasms, Nivolumab, Chemoradiotherapy, Papillomavirus Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Patients with human papillomavirus (HPV)–positive oropharyngeal cancer (OPC) and advanced stage and/or significant smoking history are at higher risk of relapse. Induction immunotherapy before chemoradiation (CRT) may improve outcomes. This randomized phase II trial assessed the feasibility and safety of induction nivolumab before CRT in this high-risk population. METHODS Eligible patients had HPV-positive OPC with either T4 and/or N2/N3 disease or a smoking history >10 pack-years. Patients were randomly assigned 1:2 to receive either standard CRT (70 Gy with cisplatin, control arm [CA], n = 20) or two infusions of nivolumab followed by CRT (experimental arm [EA], n = 41). The primary end point was the rate of patients who received full treatment in due time (FTDT), defined as (1) two nivolumab infusions on days 1 and 13-17, (2) CRT started between days 27-37 after the first nivolumab infusion, (3) no radiotherapy break ≥7 days, (4) >95% of theoretical/prescribed RT dose, and (5) cisplatin dose received ≥200 mg/m 2 . If two patients or less in the EA failed FTDT, the strategy would be considered feasible. Secondary end points included oncologic outcomes and toxicity. RESULTS Between July 2019 and September 2021, 62 patients were randomly assigned. Median follow-up was 37.5 months. The primary end point was not met: four of 41 patients in EA received

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oropharyngeal NeoplasmsNivolumabChemoradiotherapyPapillomavirus InfectionsHuman Papillomavirus VirusesAntineoplastic Agents, ImmunologicalHumansFemaleMiddle AgedMaleAgedInduction ChemotherapyCisplatinAdultPapillomaviridae

Substanzen

NivolumabCisplatinAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Oto-rhino-laryngology and Head and Neck Surgery, Hôpital Européen Georges Pompidou, AP-HP, University Paris Cité, Paris, France.
  • University Paris Cité, INSERM U970, PARCC, Paris, France.
  • Biostatistics and Epidemiology Office, Gustave Roussy, Inserm U1018 Oncostat, Ligue Contre le Cancer, University Paris-Saclay, Villejuif, France.
  • Department of Medical Oncology, Gustave Roussy, Villejuif, France.
  • Department of Medical Oncology, Centre Léon Bérard, Lyon, France.
  • Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre lès Nancy, France.

ORCID-Profile: Haitham Mirghani, Anne Aupérin, Jerome Fayette, Florian Clatot, France Nguyen, Emmanuelle Fabiano, Francois Bidault, Benjamin Morin, Eric Tartour, Laure Monard, Cecile Badoual, Pierre Blanchard

Zitieren

APA

Mirghani, H., Aupérin, A., Even, C., Larive, A., Fayette, J., Geoffrois, L., Clatot, F., Calderon, B., Tao, Y., Nguyen, F., Fabiano, E., Kreps, S., Gaultier, A. L., Bidault, F., Puech, J., Morin, B., Picavet, L., Tartour, E., Ben Hariz, A., …, & Blanchard, P. (2026). Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus–Driven Oropharynx Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-00835

Vancouver

Mirghani H, Aupérin A, Even C, Larive A, Fayette J, Geoffrois L, et al. Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus–Driven Oropharynx Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial. Journal of Clinical Oncology. 2026. doi:10.1200/jco-25-00835

BibTeX
@article{Mirghani2026,
  author = {Mirghani, Haitham and Aupérin, Anne and Even, Caroline and Larive, Alicia and Fayette, Jerome and Geoffrois, Lionnel and Clatot, Florian and Calderon, Benoit and Tao, Yungan and Nguyen, France and Fabiano, Emmanuelle and Kreps, Sarah and Gaultier, Anne-Laure and Bidault, Francois and Puech, Julien and Morin, Benjamin and Picavet, Lea and Tartour, Eric and Ben Hariz, Aicha and Chevrot, Michael and Monard, Laure and Veyer, David and Badoual, Cecile and Péré, Helene and Blanchard, Pierre},
  title = {Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus–Driven Oropharynx Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1200/jco-25-00835}
}
Kostenlos starten →